Citizens raises Mirum Pharmaceuticals price target on pipeline progress
Citizens raised its price target for Mirum Pharmaceuticals (MIRM) to $167 from $144, citing Livmarli's growth and a diversified pipeline. The company reported 44% revenue growth and 81.7% gross margin. Mirum's Q3 2026 revenue of $185.7M beat estimates, though it posted a wider-than-expected loss per share. The stock has a Strong Buy consensus with targets ranging from $118 to $200.
How this was made
The 30-second read
Why it matters
The upgraded target may attract new buying, but investors should monitor upcoming FDA submissions and execution risk.
Market read
Analyst price‑target increase provides a fresh catalyst for MIRM, potentially prompting short‑term buying pressure.
What to watch
Potential dilution from future financing rounds and competition in rare‑disease space.
Background
Citizens' upgrade follows Mirum's Q3 2026 results showing revenue beat but wider loss, and recent Phase 3 trial success for Livmarli.
Ticker impact
Citizens raised its price target on Mirum Pharmaceuticals (MIRM) to $167 from $144, citing strong topline growth and late‑stage pipeline progress.
likely upward pressure as investors price in the new target and pipeline optimism
The target represents ~92% upside from the current price, indicating a material re‑rating that can drive buying interest.
Market effects
Positive outlook for rare‑disease biotech sector as pipeline data supports higher valuations.
U.S. biotech investors may increase exposure to similar rare‑disease companies.
Limited to investors tracking US‑listed biotech stocks.
Counterpoint
The price target assumes successful regulatory approvals; any delay could negate upside.
Key entities
- companyMirum Pharmaceuticals
US‑listed biotech focused on rare diseases (NASDAQ:MIRM).
- analyst_firmCitizens
Equity research firm that issued the price‑target raise.
